Joule Announces Leadership Changes

Joule Announces Leadership Changes

August 19, 2013

Bedford, MA – August 19, 2013 – Joule, the leader in direct CO2-to-fuels solar conversion technology, today announced changes in executive leadership. After four years of leading Joule’s early development as CEO, William J. Sims will step out of his management role but will remain a member of the company’s board. Noubar Afeyan, co-founder and Chairman, is assuming the role of interim-CEO while Paul Snaith, who joined the company in 2012, will be promoted to President and COO of Joule.

BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer

BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer

August 19, 2013

Second of Two Phase 2 Clinical Studies Initiated with BIND-014 in 2013

Paul Meister Joins Quanterix Board of Directors

Paul Meister Joins Quanterix Board of Directors

August 15, 2013

LEXINGTON, Mass., Aug 15, 2013 (BUSINESS WIRE) -- Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Paul Meister to its Board of Directors.

Receptos Announces Issuance of Composition of Matter Patents Covering Proprietary Lead Product Candidate RPC1063

Receptos Announces Issuance of Composition of Matter Patents Covering Proprietary Lead Product Candidate RPC1063

August 13, 2013

SAN DIEGO, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Nos. 8,466,183 and 8,481,573 which cover compounds including the Company's proprietary selective sphingosine-1-phosphate 1 receptor (S1P1R) modulator, RPC1063. These composition of matter patents will have an initial patent term extending to May 2029.

Tetraphase Pharmaceuticals Inc.: Tetraphase Reports Second Quarter 2013 Financial Results

Tetraphase Pharmaceuticals Inc.: Tetraphase Reports Second Quarter 2013 Financial Results

August 12, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter ended June 30, 2013.

BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering

BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering

August 12, 2013

Cambridge, MA, August 12, 2013 — BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by BIND. The number of shares to be offered and the price range for the offering have not yet been determined.

BG Medicine Reports 2013 Second Quarter Financial Results and Provides Second Half Outlook

BG Medicine Reports 2013 Second Quarter Financial Results and Provides Second Half Outlook

August 8, 2013

Focusing Investments on Increasing U.S. and EU Galectin-3 Adoption

2013 Financial and Operational Guidance Provided

Receptos Reports Second Quarter 2013 Financial Results

Receptos Reports Second Quarter 2013 Financial Results

August 7, 2013

SAN DIEGO, Aug 07, 2013 (GLOBE NEWSWIRE via COMTEX) -- - Phase 2 trials of RPC1063 continue to enroll patients globally -

- Company capitalized to complete current Phase 2 trials -

- Additional Phase 1 results of RPC1063 to be presented at ECTRIMS -

Acceleron Files Registration Statement for Proposed Initial Public Offering

Acceleron Files Registration Statement for Proposed Initial Public Offering

August 7, 2013

Cambridge, Mass. – August 7, 2013 – Acceleron Pharma, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.

Ensemble Therapeutics Forms Global Strategic Collaboration for Development of Oral, Macrocyclic IL-17 Antagonists and Additional Disease Targets

Ensemble Therapeutics Forms Global Strategic Collaboration for Development of Oral, Macrocyclic IL-17 Antagonists and Additional Disease Targets

August 6, 2013

Collaboration to Accelerate Ensemble’s Novel, Oral, Interleukin-17 Inhibitor Program, and to Leverage Ensemble’s Innovative Drug Discovery Chemistry Platforms Against Certain Other Targets